Atp Announces $40 Million In Series A Funding For Srrna Therapeutics Trailblazer Replicate Bioscience

Sep 08, 2021•almost 4 years ago

Amount Raised

$40 Million

Round Type

series a

New YorkFinancial Services

Description

ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat autoimmune and inflammatory disorders and other diseases, using self-replicating RNA (srRNA). Replicate will use $40 million in committed Series A funding from ATP to advance multiple novel srRNA programs into clinical development.

Company Information

Company

Atp

Location

New York, New York, United States

About

Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP's strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech